Compare EDRY & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDRY | BOLD |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.6M | 57.5M |
| IPO Year | 2018 | 2024 |
| Metric | EDRY | BOLD |
|---|---|---|
| Price | $26.00 | $2.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 82.9K | ★ 183.0K |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.30 | N/A |
| Revenue Next Year | $10.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.00 | $0.96 |
| 52 Week High | $28.00 | $2.79 |
| Indicator | EDRY | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 63.51 | 65.12 |
| Support Level | $18.21 | $2.35 |
| Resistance Level | $28.00 | $2.64 |
| Average True Range (ATR) | 1.53 | 0.09 |
| MACD | 0.25 | -0.03 |
| Stochastic Oscillator | 93.90 | 51.11 |
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.